Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498288 | 1.00 | XPO1 (0.38) | XPO1MDM2ABL1CHEK1KDM4E | |
| SCHEMBL1702474 | 0.81 | XPO1 (0.45) | XPO1MDM2ABL1CHEK1KDM4E | |
| SCHEMBL31219517 | 0.79 | RPS6KA3 (0.46) | XPO1MDM2KDM4ENPC1LMNA | |
| SCHEMBL1705885 | 0.79 | RPS6KA3 (0.46) | XPO1MDM2KDM4ENPC1LMNA | |
| SCHEMBL1702136 | 0.77 | KARS1 (0.43) | XPO1KDM4ENPC1LMNATP53 | |
| SCHEMBL1702718 | 0.75 | CLK4 (0.47) | XPO1ABL1KDM4ENPC1LMNA | |
| SCHEMBL25853864 | 0.75 | XPO1 (0.48) | XPO1MDM2ABL1CHEK1KDM4E | |
| SCHEMBL1705808 | 0.74 | BTK (0.44) | XPO1MDM2CHEK1KDM4ENPC1 | |
| SCHEMBL31026272 | 0.73 | XPO1 (0.35) | XPO1MDM2ABL1CHEK1KDM4E | |
| SCHEMBL17434794 | 0.72 | NTRK1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117205212-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-12 | — | — | CN | claimed |
| CN-107207463-B | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-10-24 | — | — | CN | claimed |
| EP-3169328-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2022-03-09 | — | — | EP | claimed |
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2019-10-08 | — | — | US | claimed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | claimed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | claimed |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | ABIVAX (FR) | 2025-03-27 | — | — | US | disclosed |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | ABIVAX (FR) | 2025-01-21 | — | — | US | disclosed |
| EP-3998070-B1 | MIR-124 AS A BIOMARKER FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2024-12-18 | — | — | EP | disclosed |
| CN-117568459-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117281805-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| EP-3169328-A2 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016009065-A2 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2016-01-21 | — | — | WO | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | NR1I3, NR3C2, NR1I2 | XPO1 1411/4885MDM2 4684/4885ABL1 2343/4885 |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | CD14, MYADM, SYNCRIP | XPO1 1434/4885MDM2 3467/4885ABL1 1074/4885 |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | SSB, SYVN1, TLR7 | XPO1 559/4885MDM2 4318/4885ABL1 193/4885 |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | NR1I2, NR3C2, NR1I3 | XPO1 1355/4885MDM2 4643/4885ABL1 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.